An announcement from Medivir AB ( (SE:MVIR) ) is now available.
At its recent annual general meeting, Medivir AB approved the financial statements for 2024, discharged board members from liability, and decided to carry forward the company’s profits. The meeting also re-elected board members and the auditor, approved remuneration proposals, and authorized the board to issue new shares up to 20% of the total outstanding shares, providing flexibility for capital acquisition to finance operations. These resolutions are expected to impact Medivir’s operational flexibility and financial strategy, potentially influencing its market positioning and stakeholder interests.
More about Medivir AB
Medivir is a pharmaceutical company focused on developing innovative cancer drugs, particularly targeting areas with high unmet medical needs. Their primary product in development is fostroxacitabine bralpamide (fostrox), aimed at treating liver cancer cells selectively while minimizing side effects. The company emphasizes collaborations and partnerships in its business model and is listed on Nasdaq Stockholm’s Small Cap list.
Average Trading Volume: 428,630
Current Market Cap: SEK180.8M
See more data about MVIR stock on TipRanks’ Stock Analysis page.